Jubilant Pharmova announces completion of USFDA audit of facility Located at Spokane, Washington, USA

Jubilant Pharmova Limited ('Company') today announced that the United States Food and Drug Administration (USFDA) has concluded an audit of the Jubilant HollisterStier LLC's Allergy immunotherapy facility and Contract manufacturing facility, both located in Spokane, Washington (USA) from September 18 to 25, 2024. The inspection concluded with no observations.

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., USA, which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of the company.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 1178.60 as compared to the previous close of Rs. 1209.65. The total number of shares traded during the day was 7977 in over 713 trades.

The stock hit an intraday high of Rs. 1242.05 and intraday low of 1171.80. The net turnover during the day was Rs. 9604392.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 JubilantHollisterStierLLC USFDA Audit Allergy Immunotherapy Facility ContractManufacturingFacility Spokane